While there is no efficient targeted therapy against wild type BRAF melanomas, BRAF mutant (mutBRAF) melanomas are addicted to the MAPK-pathway and small molecule inhibitors targeting either mutBRAF or MEK have shown impressive clinical responses [4-7]. This evidence concerns the gene BRAF and melanoma.